Generic Cutivate Availability
CUTIVATE (fluticasone propionate - cream;topical)
Manufacturer: FOUGERA PHARMS
Approval date: December 18, 1990
Strength(s): 0.05% [RLD]
CUTIVATE (fluticasone propionate - lotion;topical)
CUTIVATE (fluticasone propionate - ointment;topical)
Has a generic version of Cutivate been approved?
A generic version of Cutivate has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Cutivate and have been approved by the FDA:
Manufacturer: GLENMARK GENERICS
Approval date: May 2, 2011
Strength(s): 0.05% [AB]
Manufacturer: PERRIGO ISRAEL
Approval date: July 30, 2013
Strength(s): 0.05% [AB]
Manufacturer: G AND W LABS
Approval date: March 3, 2006
Strength(s): 0.005% [AB]
Manufacturer: PERRIGO NEW YORK
Approval date: May 14, 2004
Strength(s): 0.005% [AB]
Note: No generic formulation of the following product is available.
- fluticasone propionate - cream;topical
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cutivate. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Fluticasone lotion having improved vasoconstrictor activity
Issued: November 27, 2007
Inventor(s): Dow; Gordon J. & Johnson; Keith Arthur & Kelly; Frances Furr & Lathrop; Robert William & Rajagopalan; Rukmini
Assignee(s): Altana Inc.
A fluticasone lotion having improved vasoconstrictor and anti-inflammatory activity and higher than expected potency. The fluticasone lotion contains 0.05 weight percent fluticasone propionate and an oil-in-water vehicle that includes excipients. The fluticasone lotion is unexpectedly efficacious while exhibiting an improved safety profile.Patent expiration dates:
- October 20, 2019✓✓
- October 20, 2019
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- January 16, 2018 - NEW PATIENT POPULATION
More about Cutivate (fluticasone topical)
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Compare Alternatives
- Support Group
- Pricing & Coupons
- En Español
- 4 Reviews – Add your own review/rating
- Generic Availability
- Drug class: topical steroids
- Cutivate (Fluticasone Cream and Lotion)
- Cutivate (Fluticasone Ointment)
- Cutivate Topical application (Advanced Reading)
Related treatment guides
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|
|AB||Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.|